debt_leverage_profile
Minimal debt; pre-revenue clinical-stage biotech funded primarily by equity raises; effectively zero leverage with ~$10-15M cash runway
Inferred
Agent_Inference
interest_rate_sensitivity
Negligible direct sensitivity; no significant floating-rate debt; higher rates increase equity dilution cost as capital raises become more expensive
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API manufacturer concentration risk (single CMO for tecarfarin API); potential China/India active pharmaceutical ingredient sourcing chokepoints
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue; USD-denominated operations only; sovereign currency devaluation exposure is effectively null at current stage
Inferred
Agent_Inference
geographic_footprint
Solely US-focused clinical operations; no international revenue markets currently; currency devaluation exposure is not applicable
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CMO dependency for tecarfarin manufacturing likely exceeds 30% operational input; non-substitutable in short term without significant regulatory delay
Inferred
Agent_Inference
business_model_type_primary
Pre-commercial pharmaceutical developer; no cloud-dependent revenue model; cloud infrastructure disruption would affect operations but not destroy core drug IP
Inferred
Agent_Inference
business_model_type_secondary
Clinical-stage biotech; secondary model is potential licensing/partnership; cloud termination minimally impacts core value which resides in drug candidate IP
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; clinical data managed via standard EDC platforms (Medidata/Veeva); switching feasible but costly in time during active trials
Inferred
Agent_Inference
howey_test_risk_index
Low Howey Test risk; revenue model is pharmaceutical drug sales/licensing, not investment contracts; equity securities already registered
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR/CCPA exposure limited to clinical trial patient data; standard IRB/ICH-GCP frameworks apply; no consumer data monetization
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust risk; small-cap niche orphan drug developer targeting anticoagulation; no market dominance or exclusionary conduct concerns
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Zero current revenue; future model is 100% transactional/milestone-based pharmaceutical sales or licensing fees upon commercialization
Inferred
Agent_Inference
monetization_vector
Drug product sales post-approval and potential out-licensing royalties/milestones for tecarfarin in ESRD anticoagulation indication
Inferred
Agent_Inference
pricing_architecture
Orphan drug pricing model anticipated; tecarfarin likely priced at premium vs. warfarin given ESRD niche; pricing power contingent on FDA approval and label
Inferred
Agent_Inference
pricing_power_rating
Moderate-high pricing power in orphan/rare disease context; limited dialysis-compatible anticoagulant alternatives creates defensible pricing position
Inferred
Agent_Inference
target_gross_margin_bracket
Pharmaceutical gross margins typically 70-85% at scale; pre-revenue stage makes current margin irrelevant; target bracket 75-85% post-commercialization
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; prescription drug model with physician-gated access; patient compliance risk exists but structural free-riding is not applicable
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear in early commercialization phase; small team (~10 employees); scaling sales force required proportionally upon launch
Inferred
Agent_Inference
marginal_cost_of_growth
Pre-revenue; future marginal cost of growth is moderate; drug manufacturing COGS fixed-cost-heavy at scale but sales force build is largely linear
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; regulatory compliance risk is FDA/EMA drug approval pathway, not franchise drift
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC efficiency improves via KOL medical education leverage; nephrology is concentrated specialty (~7,000 US nephrologists) enabling targeted detailing
Inferred
Agent_Inference
network_effect_present
No network effects present; pharmaceutical product adoption is physician/patient driven without compounding network dynamics
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low; core asset is tecarfarin drug IP and clinical data; AI cannot displace FDA-approved drug candidates or clinical trial results
Inferred
Agent_Inference
recession_resistance_tier
High recession resistance; ESRD patients require anticoagulation regardless of economic cycle; dialysis is non-discretionary life-sustaining therapy
Inferred
Agent_Inference
customer_segment_primary
ESRD patients on dialysis requiring anticoagulation; ~550,000 US dialysis patients representing concentrated addressable population
Inferred
Agent_Inference
customer_segment_secondary
Nephrology specialists and dialysis centers (DaVita, Fresenius) as prescriber/channel customers; high concentration among two major dialysis operators
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated entirely to clinical development (Phase 3 trial) and regulatory advancement; no legacy infrastructure; all spend is future-state drug commercialization
Inferred
Agent_Inference
sec_cik
0001937993
High
SEC-EDGAR
ticker
CVKD
High
SEC-EDGAR